$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000159075018000018 Filed on August 08, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$944.0K	$2.182M	$718.0K
YoY Change	-42.12%	203.9%	-65.96%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.700M	$2.670M	$2.580M
YoY Change	8.0%	3.49%	46.18%
% of Gross Profit
Research & Development	$7.399M	$8.375M	$5.487M
YoY Change	47.45%	52.63%	63.55%
% of Gross Profit
Depreciation & Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$10.10M	$11.04M	$8.068M
YoY Change	34.24%	36.87%	76.74%
Operating Profit	-$9.151M	-$8.861M	-$7.350M
YoY Change	55.39%	20.56%	113.04%
Interest Expense	$140.0K	$150.0K	$40.00K
YoY Change	133.33%	275.0%	73.91%
% of Operating Profit
Other Income/Expense, Net	$362.0K	$361.0K	$102.0K
YoY Change	220.35%	253.92%	1033.33%
Pretax Income	-$9.010M	-$8.710M	-$7.310M
YoY Change	54.55%	19.15%	107.67%
Income Tax
% Of Pretax Income
Net Earnings	-$9.011M	-$8.714M	-$7.312M
YoY Change	54.46%	19.17%	107.49%
Net Earnings / Revenue	-954.56%	-399.36%	-1018.38%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.395M	-$4.312M	-$5.112M
COMMON SHARES
Basic Shares Outstanding	30.60M shares	30.19M shares	21.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.50M	$76.30M	$46.30M
YoY Change	64.72%	64.79%	612.31%
Cash & Equivalents	$31.70M	$43.40M	$46.34M
Short-Term Investments	$38.80M	$32.90M
Other Short-Term Assets	$3.800M	$3.800M	$2.500M
YoY Change	26.67%	52.0%	316.67%
Inventory
Prepaid Expenses
Receivables	$1.382M	$1.198M	$539.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$75.75M	$81.22M	$49.35M
YoY Change	63.18%	64.59%	519.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$751.0K	$614.0K	$626.0K
YoY Change	23.11%	-1.92%	-41.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$50.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$801.0K	$664.0K	$676.0K
YoY Change	21.36%	-1.78%	-37.17%
TOTAL ASSETS
Total Short-Term Assets	$75.75M	$81.22M	$49.35M
Total Long-Term Assets	$801.0K	$664.0K	$676.0K
Total Assets	$76.55M	$81.89M	$50.03M
YoY Change	62.6%	63.69%	453.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.206M	$461.0K	$632.0K
YoY Change	194.87%	-27.06%	572.34%
Accrued Expenses	$4.336M	$3.534M	$4.019M
YoY Change	4.68%	-12.07%	201.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$1.300M	$300.0K	$2.000M
YoY Change	-35.0%	-85.0%
Total Short-Term Liabilities	$6.833M	$4.284M	$6.630M
YoY Change	4.58%	-35.38%	155.29%
LONG-TERM LIABILITIES
Long-Term Debt	$8.900M	$9.800M	$1.900M
YoY Change	535.71%	415.79%
Other Long-Term Liabilities	$88.00K	$110.0K	$189.0K
YoY Change	-48.54%	-41.8%	2262.5%
Total Long-Term Liabilities	$88.00K	$110.0K	$189.0K
YoY Change	-48.54%	-41.8%	2262.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.833M	$4.284M	$6.630M
Total Long-Term Liabilities	$88.00K	$110.0K	$189.0K
Total Liabilities	$15.84M	$14.22M	$8.690M
YoY Change	95.59%	63.59%	233.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.0M	-$107.0M	-$81.37M
YoY Change	32.99%	31.45%	250.25%
Common Stock	$308.0K	$306.0K	$215.0K
YoY Change	40.64%	42.33%	99.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$60.72M	$67.67M	$41.34M
YoY Change
Total Liabilities & Shareholders Equity	$76.55M	$81.89M	$50.03M
YoY Change	62.6%	63.69%	453.26%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$9.011M	-$8.714M	-$7.312M
YoY Change	54.46%	19.17%	107.49%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
Cash From Operating Activities	-$6.800M	-$4.510M	-$7.080M
YoY Change	20.14%	-36.3%	252.24%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$90.00K	-$110.0K
YoY Change	233.33%	-18.18%
Acquisitions
YoY Change
Other Investing Activities	-$5.800M	-$32.80M	$0.00
YoY Change
Cash From Investing Activities	-$6.020M	-$32.88M	-$110.0K
YoY Change	9933.33%	29790.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.120M	2.700M	-760.0K
YoY Change	-49.09%	-455.26%	1420.0%
NET CHANGE
Cash From Operating Activities	-6.800M	-4.510M	-7.080M
Cash From Investing Activities	-6.020M	-32.88M	-110.0K
Cash From Financing Activities	1.120M	2.700M	-760.0K
Net Change In Cash	-11.70M	-34.69M	-7.950M
YoY Change	232.39%	336.35%	285.92%
FREE CASH FLOW
Cash From Operating Activities	-$6.800M	-$4.510M	-$7.080M
Capital Expenditures	-$200.0K	-$90.00K	-$110.0K
Free Cash Flow	-$6.600M	-$4.420M	-$6.970M
YoY Change	17.86%	-36.59%	246.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30597199	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	MIRAGEN THERAPEUTICS, INC.
	mgen	Accretionof Offering Costs AccretionofOfferingCosts	5000	USD
	mgen	Accretionof Offering Costs AccretionofOfferingCosts	0	USD
CY2017Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	185000	USD
CY2018Q2	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	408000	USD
CY2017Q4	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	197000	USD
CY2018Q2	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	114000	USD
CY2017Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2018Q2	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2017Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	581000	USD
CY2018Q2	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1595000	USD
	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	0	USD
	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	54000	USD
CY2018Q2	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	105000000	shares
CY2017Q4	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	1100000	USD
CY2018Q2	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	1400000	USD
	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	51000	USD
	mgen	Conversionof Warrantsto Permanent Equity ConversionofWarrantstoPermanentEquity	0	USD
	mgen	License Fee Expense Milestone Reached LicenseFeeExpenseMilestoneReached	700000	USD
CY2017Q4	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	41000	USD
CY2018Q2	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	203000	USD
CY2017Q2	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
CY2018Q2	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
	mgen	Sale Of Stock Weighted Average Share Price SaleOfStockWeightedAverageSharePrice	8.74
	mgen	Sale Of Stock Weighted Average Share Price SaleOfStockWeightedAverageSharePrice	7.37
	mgen	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding	0.04
CY2018Q2	mgen	Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding	1741681	shares
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	906000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	461000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1456000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	131877000	USD
CY2018Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	32900000	USD
CY2018Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	32900000	USD
CY2018Q2	us-gaap	Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1280000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1198000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	61000	USD
	us-gaap	Accretion Expense AccretionExpense	61000	USD
	us-gaap	Accretion Expense AccretionExpense	189000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2991000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3534000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	232000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	78000	USD
CY2017Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	74000	USD
CY2018Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	80000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2835000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2947000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	174329000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1774000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1014000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1774000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3029000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3587000	shares
CY2017Q4	us-gaap	Assets Assets	52481000	USD
CY2018Q2	us-gaap	Assets Assets	81887000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	51868000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	81223000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22104000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46335000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47441000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43402000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	24231000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-4039000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	759359	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22568006	shares
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-445000	USD
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30595793	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22568006	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30595793	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	226000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	306000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7312000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14292000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8710000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13371000	USD
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2018Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	119000	USD
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	92000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	57000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2017Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	148000	USD
CY2018Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1538000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1021000	USD
CY2018Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	10100000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M6D
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2581000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5862000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2668000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5658000	USD
CY2017Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2017Q1	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-398000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	519000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-258000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1007000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	501000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	268000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	846000	USD
CY2017Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	64000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	135000	USD
CY2018Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	214000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	423000	USD
	us-gaap	Interest Paid InterestPaid	77000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14292000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-8714000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13375000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7312000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14297000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8714000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13375000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	1076000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	102000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	132000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	361000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	528000	USD
	us-gaap	Interest Paid InterestPaid	232000	USD
CY2017Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2018Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	13971000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	14216000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52481000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81887000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3897000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4284000	USD
CY2018Q2	us-gaap	Long Term Debt LongTermDebt	10000000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3667000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4000000	USD
CY2018Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2333000	USD
CY2017Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	9922000	USD
CY2018Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	9822000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38361000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40812000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1131000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32984000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15261000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11867000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-7312000	USD
CY2017Q4	us-gaap	Notes Payable NotesPayable	9922000	USD
CY2018Q2	us-gaap	Notes Payable NotesPayable	10111000	USD
CY2017Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2018Q2	us-gaap	Notes Payable Current NotesPayableCurrent	289000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	8068000	USD
	us-gaap	Operating Expenses OperatingExpenses	15469000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	11043000	USD
	us-gaap	Operating Expenses OperatingExpenses	20446000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7350000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14289000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8861000	USD
	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	50000000	USD
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1213386	shares
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	372852	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	1014000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1774000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13480000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	877000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	196000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	614000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	76981000	USD
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1000000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	277000	USD
CY2018Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	404000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	156000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	4000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	4000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	152000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	110000	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	32795000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	149000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	189000	USD
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2971000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3763000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40700000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10200000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2700000	USD
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	0	USD
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	110000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	148000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	146000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3398000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3561000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	563000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5487000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9607000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8375000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14788000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93593000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-106968000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	718000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1180000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2182000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6966000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	902720	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4182404	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	32860000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	110000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	146000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	38510000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	67671000	USD
CY2017Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	5000	USD
CY2018Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21409708	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16509719	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30295200	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28399687	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001590750-18-000018-index-headers.html	Edgar Link	pending
0001590750-18-000018-index.html	Edgar Link	pending
0001590750-18-000018.txt	Edgar Link	pending
0001590750-18-000018-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mgen-06302018x10q.htm	Edgar Link	pending
mgen-06302018xex311.htm	Edgar Link	pending
mgen-06302018xex312.htm	Edgar Link	pending
mgen-06302018xex321.htm	Edgar Link	pending
mgen-20180630.xml	Edgar Link	completed
mgen-20180630.xsd	Edgar Link	pending
mgen-20180630_cal.xml	Edgar Link	unprocessable
mgen-20180630_def.xml	Edgar Link	unprocessable
mgen-20180630_lab.xml	Edgar Link	unprocessable
mgen-20180630_pre.xml	Edgar Link	unprocessable
mgen06302018ex102.htm	Edgar Link	pending
mgen06302018ex102001.jpg	Edgar Link	pending
mgen06302018ex103.htm	Edgar Link	pending
mgen06302018ex103001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2018 Q3 Form 10-Q Financial Statement

#000159075018000018 Filed on August 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2018 Q3 Form 10-Q Financial Statement

#000159075018000018 Filed on August 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn